The 35Pharma acquisition comes as GSK looks to stock up its pipeline amid the looming patent expiries soon to impact its ...

GSK PLC agreed to buy 35Pharma Inc., a biotech with an early-stage drug for pulmonary hypertension, as the United Kingdom ...

GSK acquires 35Pharma for $950M. The primary focus is HS235, a selective PH drug reducing bleeding risk with metabolic ...

This deal adds two more siRNA candidates to GSK’s pipeline, which the company is looking to expand as it looks to offset the ...

GSK has entered an agreement to acquire Canadian biotechnology company 35Pharma for $950 million in order to strengthen its pipeline of therapies for pulmonary hypertension and related cardiopulmonary ...

GlaxoSmithKline has made a hire signaling its commitment to digital health. Karenann Terrell, former Chief Information Officer at Walmart, will start at GSK in the newly created role of Chief Digital ...

Pharma giant GSK is launching a five-year collaboration with The Jackson Laboratory–New York Stem Cell Foundation Collaborative (JAX-NYSCF) to advance human cellular models of neurodegenerative ...

The European approval for GSK's depemokimab joins recently announced data on vaccine efficacy and progress on 4-month viral treatments.

GSK has received US Food and Drug Administration (FDA) approval for Blenrep (belantamab mafodotin-blmf) to be used along with bortezomib and dexamethasone for multiple myeloma. This combination is ...

Settlement reached over mRNA-based COVID vaccines CureVac and GSK get $740 million upfront, and royalties BioNTech's deal to buy CureVac on track GSK's own lawsuits against Pfizer, BioNTech unaffected ...